Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
March 15, 2024
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
March 15, 2024 —  BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions…
Read More
Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
March 15, 2024
Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports
March 15, 2024 —Renowned cardiovascular surgeon Gilbert H. L. Tang, MD, has been named Editor-in-Chief of JACC: Case…
Read More
In a new letter sent to federal officials on March 12, the American Medical Association (AMA) has presented six relief proposals to support physicians impacted by Change Healthcare hack, and praised the creation of the Change Healthcare/Optum Payment Disruption (CHOPD) Accelerated Payments.
March 14, 2024
AMA Presents Relief Proposals to Federal Officials to Support Physicians Impacted by Change Healthcare Hack
March 14, 2024 — The American Medical Association (AMA) has issued a new letter to federal officials in which it…
Read More
First-of-its-kind trial in US shows drug-coated balloons are a superior treatment option for patients undergoing coronary angioplasty
March 13, 2024
BIDMC-led Trial Leads to FDA approval of Coronary Drug-coated Balloons
March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team…
Read More
BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.
March 13, 2024
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
March 13, 2024 —  BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of…
Read More
New Jersey-based Atlantic Health System’s Morristown Medical Center and New York-based NYU Langone Health, both nationally recognized cardiovascular programs, have announced that they are expanding their partnership to provide patients improved access to adult congenital heart disease services and the specialist directed care. Shown here, Trish O’Keefe, Senior Vice President, and President of Morristown Medical Center.
March 13, 2024
Atlantic Health System’s Morristown Medical Center and NYU Langone Health Expand Partnership to Include Adult Congenital Heart Disease
March 13, 2024 — Two nationally recognized cardiovascular programs, New Jersey-based Atlantic Health System’s…
Read More
Silence Therapeutics has announces positive topline 36-week data from its ongoing Phase 2 Study of Zerlasiran in patients with high Lipoprotein(a), reporting that the study met the primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36.
March 13, 2024
Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lp(a) Announced by Silence Therapeutics
March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2…
Read More
Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States
March 12, 2024
New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform
March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data…
Read More
Physicians at Vilnius University Hospital. Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States
March 12, 2024
Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
March 12, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular…
Read More
Getinge has announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company’s endoscopic vessel harvesting (EVH) solutions.
March 12, 2024
Getinge Announces US FDA 510(k) Clearance for Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) solution
March 12, 2024 — Getinge has announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of the Vasoview…
Read More
The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling its HeartMate Touch System (version 1.0.32) for risk of unexpected pump stop or start. Issues may occur if the HeartMate Touch System is disconnected from a patient’s HeartMate Controller while a “pump stop” command is running. People who have the implantable HeartMate 3 Left Ventricular Assist Device may be affected.
March 12, 2024
FDA Announces Abbott Recall of HeartMate Touch Communication System for Unintentional Pump Start and Stop
March 12, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling its HeartMate Touch…
Read More
VahatiCor, Inc., a med tech company dedicated to helping patients with persistent ischemic heart disease, has announced the treatment of the first patient with the A-FLUX Reducer System, a treatment for patients with angina or chest pain.
March 11, 2024
VahatiCor, Inc. Announces Treatment of First Patient with the A-FLUX Reducer System Innovation for Patients Suffering from Angina Due to Persistent Ischemic Heart Disease
March 11, 2024 — VahatiCor, Inc., a med tech company dedicated to helping patients with persistent ischemic heart…
Read More
Georgia Tech-led effort to improve support device options for end-stage heart failure
March 08, 2024
The Texas Heart Institute Collaborates on Multi-institutional DOD Grant to Develop Novel Left Ventricular Assist Device
March 8, 2024 —  The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State…
Read More
Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States
March 08, 2024
Silk Road Medical Expands TCAR Portfolio with Launch of Tapered ENROUTE Transcarotid Stent System
March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact,…
Read More
The approval is based on the results of SELECT, the largest cardiovascular outcomes trial ever completed for people with obesity and known heart disease
March 08, 2024
FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity
March 8, 2024 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an…
Read More
Cinematic Reality app enables interaction with realistic renderings of human anatomy
March 07, 2024
Siemens Healthineers Launches Cinematic Reality App for Apple Vision Pro
March 7, 2024 — Siemens Healthineers has launched an app designed for Apple Vision Pro that enables users such as…
Read More
The company will showcase AI-enabled innovations and digital solutions that enhance clinical decision making and provide personalized patient care
March 07, 2024
GE HealthCare to Spotlight Industry-Leading AI-Enabled Portfolio and Digital Solutions at HIMSS 2024
March 7, 2024 — GE HealthCare will showcase its industry-leading portfolio of artificial intelligence (AI)-enabled…
Read More
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events
March 07, 2024
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
March 7, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions…
Read More
The American College of Cardiology (ACC) has announced its line-up of keynote speakers for the ACC 73rd Annual Scientific Session & Expo, ACC.24, including U.S. Food and Drug Administration Commissioner Robert M. Califf, MD, MACC, among a host of highly-regarded cardiovascular thought leaders and practitioners during the April 6-8 meeting in Atlanta, GA.
March 07, 2024
FDA Commissioner, Host of Cardiovascular Leaders to Offer Keynote Addresses at ACC.24
March 7, 2024 — The American College of Cardiology (ACC) has announced its line-up of keynote speakers for the ACC 73rd…
Read More
Matt Renner, President of North America and Global Startups at Google Cloud, is one of several keynote to be featured during the HIMSS 2024, the Global Conference and Exhibition of the Healthcare Information and Management Systems Society (HIMSS) to be held March 11-15 in Orlando, FL.
March 07, 2024
Google Cloud Leader and High-Profile Keynote Speakers to be Featured at HIMSS24
March 7, 2024 — With just days to go before HIMSS 2024, the Global Conference and Exhibition of the Healthcare…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now